Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation

Thrombosis Research

Volumn 120, Issue 3, 2007, Pages 439-446

  Pieters, Marlien ^a   van Zyl, Danie G ^b   Rheeder, Paul ^b   Jerling, Johann C ^a   Loots, Du Toit ^a   van der Westhuizen, Francois H ^c   Gottsche, Louise T ^a   Weisel, John W ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Glycaemic control; Glycated fibrinogen; Glycation; Type 2 diabetes

Indexed keywords

FIBRINOGEN; GLUCOSE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; GLYCEMIC CONTROL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOGEN; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED;

EID: 34249945174     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.10.016     Document Type: Article

References (36)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 5 (2004) 1047-1053
2. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 2 (1993) 434-444
3. Wei M., Gaskill S.P., Haffner S.M., and Stern M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21 7 (1998) 1167-1172
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 14 (1993) 977-986
5. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342 6 (2000) 381-389
6. Boyne M.S., and Saudek C.D. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Diabetes Care 22 Suppl 3 (1999) C45-C53
7. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 25 (2005) 2643-2653
8. Haffner S.M. Epidemiological studies on the effects of hyperglycemia and improvement of glycemic control on macrovascular events in type 2 diabetes. Diabetes Care 22 Suppl 3 (1999) C54-C56
9. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 6 (2005) 1615-1625
10. Basta G., Schmidt A.M., and De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63 4 (2004) 582-592
11. Danesh J., Lewington S., Thompson S.G., Lowe G.D., Collins R., Kostis J.B., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 14 (2005) 1799-1809
12. Dunn E.J., and Ariens R.A. Fibrinogen and fibrin clot structure in diabetes. Herz 29 5 (2004) 470-479
13. Lutjens A., te Velde A.A., vd Veen E.A., and vd M.J. Glycosylation of human fibrinogen in vivo. Diabetologia 28 2 (1985) 87-89
14. Hammer M.R., John P.N., Flynn M.D., Bellingham A.J., and Leslie R.D. Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 26 Pt 1 (1989) 58-62
15. Ardawi M.S., Nasrat H.N., Mira S.A., and Fatani H.H. Comparison of glycosylated fibrinogen, albumin, and haemoglobin as indices of blood glucose control in diabetic patients. Diabet Med 7 9 (1990) 819-824
16. Dunn E.J., Ariens R.A., and Grant P.J. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48 6 (2005) 1198-1206
17. Nair C.H., Azhar A., Wilson J.D., and Dhall D.P. Studies on fibrin network structure in human plasma. Part II-Clinical application: diabetes and antidiabetic drugs. Thromb Res 64 4 (1991) 477-485
18. Jorneskog G., Egberg N., Fagrell B., Fatah K., Hessel B., Johnsson H., et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39 12 (1996) 1519-1523
19. Kitamura M., Asai K., and Kuzuya F. Clinical significance of measuring glycated fibrinogen in plasma in diabetes mellitus. Nippon Ronen Igakkai Zasshi 29 5 (1992) 396-402
20. Suzuki S., Kokubu M., Saito E., Makise J., Kanayama M., and Yamanaka M. Assay of glycated fibrinogen in plasma as an indicator of blood glucose control. Rinsho Byori 38 3 (1990) 306-310
21. Standards of medical care in diabetes. Diabetes Care 27 Suppl 1 (2004) S15-S35
22. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 6 (1972) 499-502
23. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 7 (2000) 2402-2410
24. Takebe M., Soe G., Kohno I., Sugo T., and Matsuda M. Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost 73 4 (1995) 662-667
25. Dunn E.J., and Ariens R.A. Fibrinogen and fibrin clot structure in diabetes. Herz 29 5 (2004) 470-479
26. Jerling J.C., Vorster H.H., Oosthuizen W., Silvis N., and Venter C.S. Differences in plasminogen activator inhibitor 1 activity between blacks and whites may be diet related. Haemostasis 24 6 (1994) 364-368
27. Folsom A.R., Wu K.K., Conlan M.G., Finch A., Davis C.E., Marcucci G., et al. Distributions of hemostatic variables in blacks and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) Study. Ethn Dis 2 1 (1992) 35-46
28. Hammer M.R., John P.N., Flynn M.D., Bellingham A.J., and Leslie R.D. Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 26 Pt 1 (1989) 58-62
29. Ardawi M.S., Nasrat H.N., Mira S.A., and Fatani H.H. Comparison of glycosylated fibrinogen, albumin, and haemoglobin as indices of blood glucose control in diabetic patients. Diabet Med 7 9 (1990) 819-824
30. Suzuki S., Kokubu M., Saito E., Makise J., Kanayama M., and Yamanaka M. Assay of glycated fibrinogen in plasma as an indicator of blood glucose control. Rinsho Byori 38 3 (1990) 306-310
31. Lutjens A., te Velde A.A., vd Veen E.A., and vd MJ. Glycosylation of human fibrinogen in vivo. Diabetologia 28 2 (1985) 87-89
32. Fluckiger R., and Winterhalter K.H. In vitro synthesis of hemoglobin AIc. FEBS Lett 71 2 (1976) 356-360
33. Schleicher E., and Wieland O.H. Specific quantitation by HPLC of protein (lysine) bound glucose in human serum albumin and other glycosylated proteins. J Clin Chem Clin Biochem 19 2 (1981) 81-87
34. Austin G.E., Mullins R.H., and Morin L.G. Non-enzymic glycation of individual plasma proteins in normoglycemic and hyperglycemic patients. Clin Chem 33 12 (1987) 2220-2224
35. Kitamura M., Asai K., and Kuzuya F. Clinical significance of measuring glycated fibrinogen in plasma in diabetes mellitus. Nippon Ronen Igakkai Zasshi 29 5 (1992) 396-402
36. Rakhimova G.N., Akbarov Z.S., and Tarakulov I. Significance of glycated fibrinogen measurements in diabetes mellitus. Klin Lab Diagn 2 (1999) 18-21